McKesson Corporation $MCK Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. reduced its stake in shares of McKesson Corporation (NYSE:MCK) by 11.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 6,077 shares of the company’s stock after selling 757 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in McKesson were worth $4,985,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Obsidian Personal Planning Solutions LLC grew its holdings in McKesson by 2.9% during the 3rd quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock worth $346,000 after acquiring an additional 12 shares in the last quarter. LRI Investments LLC grew its holdings in McKesson by 12.1% during the 4th quarter. LRI Investments LLC now owns 111 shares of the company’s stock worth $91,000 after acquiring an additional 12 shares in the last quarter. Berkshire Asset Management LLC PA grew its holdings in McKesson by 4.6% during the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after acquiring an additional 13 shares in the last quarter. Norden Group LLC grew its holdings in McKesson by 4.3% during the 4th quarter. Norden Group LLC now owns 317 shares of the company’s stock worth $260,000 after acquiring an additional 13 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC grew its holdings in McKesson by 0.7% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 1,873 shares of the company’s stock worth $1,536,000 after acquiring an additional 13 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MCK has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Evercore reissued an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $875.00 price objective on shares of McKesson in a report on Friday, May 8th. Raymond James Financial set a $970.00 price target on shares of McKesson in a report on Thursday, March 5th. Finally, Bank of America decreased their price target on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a report on Monday, April 6th. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $963.20.

Insider Buying and Selling at McKesson

In other McKesson news, Director Maria Martinez sold 349 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the transaction, the director directly owned 301 shares of the company’s stock, valued at $282,900.87. The trade was a 53.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president directly owned 2,989 shares of the company’s stock, valued at $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,264 shares of company stock valued at $3,205,315 in the last ninety days. Company insiders own 0.08% of the company’s stock.

McKesson Stock Performance

NYSE MCK opened at $736.60 on Thursday. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00. The company has a 50-day simple moving average of $864.13 and a 200-day simple moving average of $858.29. The firm has a market capitalization of $88.54 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.10 and a beta of 0.35.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, beating the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The business had revenue of $96.30 billion during the quarter, compared to analyst estimates of $101.35 billion. During the same period in the previous year, the business posted $10.12 EPS. The company’s quarterly revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities analysts forecast that McKesson Corporation will post 44.29 earnings per share for the current year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s payout ratio is presently 8.53%.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.